HARRY J. LEONHARDT - 01 Mar 2024 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role: GC & Chief Compliance Officer
Signature: /s/ Harry J.Leonhardt
Issuer symbol: N/A
Transactions as of: 01 Mar 2024
Net transactions value: -$67,344
Form type: 4
Filing time: 04 Mar 2024, 17:18:40 UTC
Previous filing: 02 Mar 2023
Next filing: 08 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Award	$0	+80,743	+54%	$0.000000	230,946	01 Mar 2024	Direct	F1, F2
transaction	PSTX	Common Stock	Tax liability	$67,344	-16,306	-7.1%	$4.13	214,640	01 Mar 2024	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Employee Stock Option (Right to Buy)	Award	$0	+111,700		$0.000000	111,700	01 Mar 2024	Common Stock	111,700	$4.13	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
F2	Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2023 and 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2023.
F3	Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on March 1, 2022 and March 1, 2023.
F4	12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.